Choosing Between Revumenib and Ziftomenib for Patients With NPM1 Mutations

In this episode, Zepcan walks through the specific clinical questions pharmacists should ask when a prescriber is selecting between these agents for patients with NPM1 mutations—the only indication where both are approved. She covers transplant eligibility timelines, drug interaction burden, and QTc monitoring to help pharmacists counsel prescribers on evidence-based selection criteria.